Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Trever G. Bivona, M.D., Ph.D.
Trever G. Bivona, M.D., Ph.D.

Trever G. Bivona, M.D., Ph.D.

Assistant Professor in Residence
Division of Hematology/Oncology
Department of Medicine

Contact Information

University of California, San Francisco
Mission Bay/Genentech Hall
600 16th Street, Room: N212D
San Francisco, CA 94158-2140
UCSF intercampus mail, please use mail code: 2140 
TBivona@medicine.ucsf.edu
Phone: 415-476-9907 / Lab Fax: 415-514-0169 / Clinic Fax #: 415-514-6676

Open Popup
  • Vanderbilt University, B.S., 1998, Molecular Biology
  • New York University, School of Medicine, Ph.D., 2004, Cell and Mol. Biology
  • New York University, School of Medicine, M.D., 2005, Medicine
  • Brigham and Women's Hospital/Harvard, 2005-2007, Internal Medicine
  • Memorial Sloan-Kettering Cancer Center, 2007-2011, Medical Oncology
  • Research Fellow, Laboratory of Charles Sawyers, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 2008-2011
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology
  • Department of Medicine, Division of Hematology/Oncology
  • Thoracic Oncology Program
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • Member, UCSF Biomedical Sciences Graduate Program (BMS)
  • Member, California Institute for Quantitative Biosciences (QB3)
  • Activating mutations in EGFR
  • Lung cancer
  • Mechanisms of Secondary Resistance
  • Molecular pathogenesis of human cancers
  • Molecularly-targeted cancer therapies
  • Next-generation functional genomics
  • Novel, rational therapeutic strategies

Trever G. Bivona, M.D., Ph.D. is a thoracic medical oncologist. His overarching goal is to develop paradigm-shifting treatment strategies that target the aberrant signal transduction pathways fueling tumor growth. He is Director of the Bivona Lab, a bench-to-bedside research enterprise investigating the molecular pathogenesis of human cancers, primarily lung cancer. In pursuit of that goal, the Bivona Lab uses interdisciplinary approaches and next-generation functional genomics methodologies, highly relevant cell line and tumor model systems, and human tumor specimens and clinical outcomes data. These help to define and elucidate the molecular events driving human lung cancer growth. 

Dr. Bivona received his M.D. and Ph.D. from the joint Medical Scientist Training Program at NYU School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital followed by advanced training at Memorial Sloan-Kettering Cancer Center as a medical oncology fellow, and research fellow in the Laboratory of Charles Sawyers, Human Oncology and Pathogenesis Program.

I am a laboratory-based physician-scientist and an academic medical oncologist with a Ph.D. in cell and molecular biology. Clinical experiences inspire my laboratory investigations and provide opportunities to translate scientific discoveries aimed at improving the personalized treatment of cancer patients.  The goal of my research program is to define the molecular pathogenesis of human cancers through both basic and translational studies with a particular focus on lung cancer, the leading cause of cancer mortality in the United States.

Our aim is to discover tumor-cell specific vulnerabilities that can be therapeutically exploited as novel treatment strategies to improve the survival of patients with lung, and potentially, other cancers.  To accomplish our goals, we have a developed an integrated approach to define the molecular mechanisms by which oncogenes drive the growth of human lung cancers and by which tumors evade oncogene-targeted treatments.

Our approach leverages state-of-the-art functional genomics RNA interference screening methodologies, highly relevant preclinical models of lung cancer that accurately represent human lung cancer, and prospectively acquired human lung cancer specimens and clinical data.  Using this approach we recently identified several novel mechanisms of resistance to EGFR (epidermal growth factor receptor) inhibitors in lung cancers with activating (oncogenic) mutations in EGFR. Our work has defined new rational companion therapeutic targets that when inhibited may enhance responses to EGFR inhibitors in lung cancer patients

The studies proposed in this project build upon our prior research because they will allow us to further define molecular determinants of oncogene dependence in human lung cancers. Moreover, we are uniquely positioned to translate our findings into lung cancer patients through validation of our findings in human lung cancer specimens and, subsequently, hypothesis-driven clinical trials in lung cancer patients.

Most recent publications from a total of 77
  1. Haderk F, Olivas V, Bivona TG. Immunohistochemistry to Study YAP in Human Tissue Samples. Methods Mol Biol. 2019; 1893:89-95. View in PubMed
  2. Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Res. 2018 Dec 11. View in PubMed
  3. Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL. Compensation of select proteostasis networks after Hsp70 inhibition in cancer. J Cell Sci. 2018 Aug 21. View in PubMed
  4. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 Aug 13. View in PubMed
  5. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DS, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2018 Jun 06. View in PubMed
  6. Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest. 2018 May 07. View in PubMed
  7. Zaman A, Bivona TG. Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Ann Transl Med. 2018 May; 6(9):160. View in PubMed
  8. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 Apr 05; 173(2):321-337.e10. View in PubMed
  9. McCoach CE, Bivona TG. The evolving understanding of immunoediting and the clinical impact of immune escape. J Thorac Dis. 2018 Mar; 10(3):1248-1252. View in PubMed
  10. Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Cajal SRY, Frias A, Cao P, Rosell R. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine. 2018 Mar; 29:112-127. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Trever G. Bivona, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

Site Directory
    X